vs
Side-by-side financial comparison of ACME UNITED CORP (ACU) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $52.3M, roughly 1.4× ACME UNITED CORP). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 13.8%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -2.9%).
Acme United Corporation is a supplier of cutting, measuring and safety products for the school, home, office, hardware and industrial markets. The company was organized as a partnership in 1867 and incorporated in 1873 under the laws of the State of Connecticut. It is publicly traded on the NYSE American with symbol ACU.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
ACU vs PBYI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $52.3M | $75.5M |
| Net Profit | $985.0K | — |
| Gross Margin | 39.7% | 69.3% |
| Operating Margin | 3.3% | 22.7% |
| Net Margin | 1.9% | — |
| Revenue YoY | 13.8% | 27.7% |
| Net Profit YoY | -40.4% | — |
| EPS (diluted) | $0.24 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $52.3M | — | ||
| Q4 25 | $47.5M | $75.5M | ||
| Q3 25 | $49.1M | $54.5M | ||
| Q2 25 | $54.0M | $52.4M | ||
| Q1 25 | $46.0M | $46.0M | ||
| Q4 24 | $45.9M | $59.1M | ||
| Q3 24 | $48.2M | $80.5M | ||
| Q2 24 | $55.4M | $47.1M |
| Q1 26 | $985.0K | — | ||
| Q4 25 | $1.9M | — | ||
| Q3 25 | $1.9M | $8.8M | ||
| Q2 25 | $4.8M | $5.9M | ||
| Q1 25 | $1.7M | $3.0M | ||
| Q4 24 | $1.7M | — | ||
| Q3 24 | $2.2M | $20.3M | ||
| Q2 24 | $4.5M | $-4.5M |
| Q1 26 | 39.7% | — | ||
| Q4 25 | 38.2% | 69.3% | ||
| Q3 25 | 39.1% | 77.7% | ||
| Q2 25 | 41.0% | 76.5% | ||
| Q1 25 | 39.0% | 77.1% | ||
| Q4 24 | 38.7% | 76.4% | ||
| Q3 24 | 38.5% | 63.9% | ||
| Q2 24 | 40.8% | 77.4% |
| Q1 26 | 3.3% | — | ||
| Q4 25 | 6.1% | 22.7% | ||
| Q3 25 | 6.1% | 17.6% | ||
| Q2 25 | 11.8% | 12.7% | ||
| Q1 25 | 5.3% | 8.7% | ||
| Q4 24 | 5.0% | 22.6% | ||
| Q3 24 | 6.1% | 27.4% | ||
| Q2 24 | 11.5% | -4.6% |
| Q1 26 | 1.9% | — | ||
| Q4 25 | 3.9% | — | ||
| Q3 25 | 3.9% | 16.2% | ||
| Q2 25 | 8.8% | 11.2% | ||
| Q1 25 | 3.6% | 6.5% | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 4.6% | 25.2% | ||
| Q2 24 | 8.0% | -9.6% |
| Q1 26 | $0.24 | — | ||
| Q4 25 | $0.46 | $0.26 | ||
| Q3 25 | $0.46 | $0.17 | ||
| Q2 25 | $1.16 | $0.12 | ||
| Q1 25 | $0.41 | $0.06 | ||
| Q4 24 | $0.43 | $0.40 | ||
| Q3 24 | $0.54 | $0.41 | ||
| Q2 24 | $1.09 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.2M | $97.5M |
| Total DebtLower is stronger | $33.0M | $22.7M |
| Stockholders' EquityBook value | $116.7M | $130.3M |
| Total Assets | $195.2M | $216.3M |
| Debt / EquityLower = less leverage | 0.28× | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $4.2M | — | ||
| Q4 25 | $3.6M | $97.5M | ||
| Q3 25 | $5.1M | $94.4M | ||
| Q2 25 | $3.6M | $96.0M | ||
| Q1 25 | $3.4M | $93.2M | ||
| Q4 24 | $6.4M | $101.0M | ||
| Q3 24 | $5.7M | $96.7M | ||
| Q2 24 | $3.8M | $96.8M |
| Q1 26 | $33.0M | — | ||
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M |
| Q1 26 | $116.7M | — | ||
| Q4 25 | $117.6M | $130.3M | ||
| Q3 25 | $115.8M | $115.3M | ||
| Q2 25 | $113.7M | $104.7M | ||
| Q1 25 | $108.3M | $97.1M | ||
| Q4 24 | $107.0M | $92.1M | ||
| Q3 24 | $106.3M | $71.1M | ||
| Q2 24 | $104.0M | $48.5M |
| Q1 26 | $195.2M | — | ||
| Q4 25 | $171.0M | $216.3M | ||
| Q3 25 | $173.0M | $202.9M | ||
| Q2 25 | $170.9M | $194.9M | ||
| Q1 25 | $163.0M | $196.2M | ||
| Q4 24 | $162.2M | $213.3M | ||
| Q3 24 | $165.5M | $220.7M | ||
| Q2 24 | $173.5M | $205.0M |
| Q1 26 | 0.28× | — | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $8.2M | $14.4M | ||
| Q3 25 | $7.1M | $9.7M | ||
| Q2 25 | $6.3M | $14.1M | ||
| Q1 25 | $-3.3M | $3.6M | ||
| Q4 24 | $6.4M | $15.6M | ||
| Q3 24 | $8.9M | $11.0M | ||
| Q2 24 | $6.9M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | $7.3M | $14.4M | ||
| Q3 25 | $301.0K | $9.7M | ||
| Q2 25 | $4.7M | $14.1M | ||
| Q1 25 | $-4.7M | $3.6M | ||
| Q4 24 | $4.7M | $15.6M | ||
| Q3 24 | $7.5M | $11.0M | ||
| Q2 24 | $4.4M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | 19.1% | ||
| Q3 25 | 0.6% | 17.7% | ||
| Q2 25 | 8.7% | 26.8% | ||
| Q1 25 | -10.2% | 7.7% | ||
| Q4 24 | 10.2% | 26.4% | ||
| Q3 24 | 15.6% | 13.7% | ||
| Q2 24 | 8.0% | 2.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 0.0% | ||
| Q3 25 | 13.8% | 0.0% | ||
| Q2 25 | 3.0% | 0.0% | ||
| Q1 25 | 2.9% | 0.1% | ||
| Q4 24 | 3.7% | 0.0% | ||
| Q3 24 | 2.8% | 0.0% | ||
| Q2 24 | 4.5% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | 4.34× | — | ||
| Q3 25 | 3.72× | 1.10× | ||
| Q2 25 | 1.33× | 2.41× | ||
| Q1 25 | -2.02× | 1.21× | ||
| Q4 24 | 3.73× | — | ||
| Q3 24 | 3.99× | 0.54× | ||
| Q2 24 | 1.55× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
